Changes in the Options for Management of Prolactin Secreting Pituitary Adenomas

Content Provider	Scilit
Author	Iuliano, Sherry L. Bi, Wenya Linda Laws Jr, Edward R.
Copyright Year	2021
Description	Objectives Initial therapy for the management of prolactinomas has long been maintained to be medical, consisting of a dopamine agonist. These therapies may have troublesome side effects, and some prolactinomas are resistant to medical therapy regarding lowering prolactin levels or shrinking the tumor. These issues have revived interest in surgery for prolactin-secreting adenomas as an early therapeutic option. We report our analysis of surgery for prolactin microadenomas in women, using the transsphenoidal endoscopic approach. Design We reviewed a contemporary series of 33 women (mean age = 31.8 years) with microprolactinomas who underwent early surgical intervention, which was a three-dimensional transnasal transsphenoidal endoscopic operation. Setting The study was conducted at a tertiary academic referral center for pituitary tumors. Main Outcome Measures Preoperative and postoperative prolactin. Results Overall, 28 patients had received preoperative dopamine agonists, 24 of these experienced a variety of drug-related side effects, and 4 had tumors that were resistant to lowering prolactin or tumor shrinkage. Preoperative prolactin levels averaged 90.3 ng/mL (range = 30.7–175.8 ng/mL). We observed a 94% normalization rate in postoperative prolactin (mean = 10.08 ng/mL, range = 0.3–63.1 ng/mL). During the follow-up (mean = 33.9 months), five patients had elevated prolactin; four required reinitiation of medical therapy, two had surgical reexploration, and none received radiation therapy. Complications included syndrome of inappropriate antidiuretic hormone secretion (n = 3), transient diabetes insipidus (n = 1), postoperative epistaxis (n = 1), and fat graft site infection (n = 1). Conclusion This review supports the consideration of transsphenoidal surgery as an early intervention for some women with prolactin-secreting microadenoma. Indications include significant side effects of medical therapy and tumors that do not respond to standard medical management.
Related Links	http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1722665.pdf
Ending Page	e53
Page Count	5
Starting Page	e49
ISSN	21936331
DOI	10.1055/s-0040-1722665
Journal	Journal of Neurological Surgery Part B: Skull Base
Issue Number	S 02
Volume Number	83
Language	English
Publisher	Georg Thieme Verlag KG
Publisher Date	2021-02-18
Access Restriction	Open
Subject Keyword	Journal: Journal of Neurological Surgery Part B: Skull Base Endocrinology and Metabolism Otorhinolaryngology Dopamine Agonist Side Effects Endoscopic Transsphenoidal Surgery
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical)